Arbitration Court Supports FAS
It has already been reported in Mass Media, that because of unjustified increase of prices submitted for marketing authorization over earlier registered prices for Cyprofloxacin, Metronidazole, Elfa Laboratories, India got a refusal to authorize the above stated products.
Not agreeing with arguments of the antimonopoly authority, SC Scientific Production Center Elfa made an appeal to the Arbitration Court of the Moscow region. The arbitration court confirmed the legitimacy of FAS refusal to approve overestimated prices for the above drugs. The applicant’s cassational appeal was refused.